Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Multiplex Assay Kit for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay)
FH3; HCHOLA3; NARC1; Hypercholesterolemia,Autosomal Dominant 3; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
(Note: Up to 8-plex in one testing reaction)
- Product No.LME189Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.2-200ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.067 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 474
US$ 492
US$ 520
US$ 556
US$ 593
US$ 648
US$ 730
US$ 912
Add to Price Calculator
Result
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 92-99 | 95 |
| EDTA plasma(n=5) | 78-94 | 86 |
| heparin plasma(n=5) | 88-96 | 93 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 92-101% | 99-105% | 78-101% | 78-89% |
| EDTA plasma(n=5) | 80-92% | 78-92% | 85-103% | 85-93% |
| heparin plasma(n=5) | 97-105% | 81-92% | 93-101% | 81-97% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:PCSK9) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Biological Trace Element Research | Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers pubmed:28409410 |
| BASIC RESEARCH IN CARDIOLOGY | Autocrine effects of PCSK9 on cardiomyocytes Pubmed: 33169229 |
| J Transl Med | Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555 |
| Metabolism | MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice 33775647 |
| Eur Rev Med Pharmacol Sci | Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders 34533801 |
| Clin Exp Hypertens | Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease Pubmed:35502687 |